Molecular cancer therapeutics: Recent progress and targets in drug resistance

Internal Medicine

Volumn 42, Issue 3, 2003, Pages 237-243

  Tsuruo, Takashi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

AKT; Apoptosis resistance; Drug resistance; Glyoxalase I; Proteasome

Indexed keywords

4 BROMOBENZYLGLUTATHIONE CYCLOPENTYL DIESTER; 5 [3 (4 DIPHENYLACETYL 1 PIPERAZINYL) 2 HYDROXYPROPOXY]QUINOLINE; 7 HYDROXYSTAUROSPORINE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; CYCLOSPORIN A; CYTARABINE; DILTIAZEM; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ENZYME INHIBITOR; ETOPOSIDE; GEFITINIB; GLYCOPROTEIN P; GLYCOPROTEIN P INHIBITOR; IMATINIB; LACTOYLGLUTATHIONE LYASE; LACTOYLGLUTATHIONE LYASE INHIBITOR; MATRIX METALLOPROTEINASE INHIBITOR; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN INHIBITOR; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; TACROLIMUS; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSPODAR; VASCULOTROPIN ANTIBODY; VERAPAMIL;

APOPTOSIS; BREAST TUMOR; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL KILLING; CELL SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; LUNG NON SMALL CELL CANCER; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; TUMOR CELL;

EID: 0037367684     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.42.237     Document Type: Review

References (42)

1. Vogel, C., Cobleigh, M. and Tripathy, D. First-line, nonhormonal treatment of woman with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody). Proc Am Soc Clin Oncol 19: 71a (abstr275), 2000.
2. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in woman who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastanic disease. J Clin Oncol 17: 2639-2648, 1999.
3. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18: 2241-2251, 1999.
4. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792, 2001.
5. Burstein HJ, Kuter I, Campos SM, et al. Clinical activity of trastuzumab and vinorelbine in woman with HER2- overexpressing metastatic breast cancer. J Clin Oncol 19: 2722-2730, 2001.
6. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 341: 164-172, 1999.
7. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 105: 3-7, 2000.
8. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001.
9. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gatrointestinal stromal tumor. N Engl J Med 344: 1052-1056, 2001.
10. Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vitro. Cancer Res 61: 8887-8895, 2001.
11. Christensen JG, Schreck RE, Chan E, et al. High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo. Clin Cancer Res 7: 4230-4238, 2001.
12. Anderson NG, Ahmad T, Chan K, Dobson R, Bundred NJ. ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR- positive cancer cell lines with or without erbB2 overexpression. Int J Cancer 94: 774-782, 2001.
13. Chan KC, Knox WF, Gee JM, et al. Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res 62: 122-128, 2002.
14. Albanell J, Rojo F, Averbuch S, et al. Pharmacodynamic Studies of the epidermal growth factor receptor inhibitor ZD 1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 20: 110-124, 2002.
15. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 79: 285-296, 1988.
16. Sugimoto Y, Tsuruo T. DNA-mediated transfer and cloning of a human multidrug-resistant gene of Adriamycin-resistant myelogenous leukemia K562. Cancer Res 47: 2620-2625, 1987.
17. Hamada H, Tsuruo T. Functional role for the 170- to 180-kDa glycoprotein specific to drug- resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 83: 7785-7789, 1986.
18. Hamada H, Tsuruo T. Purification of the 170- to 180-kilodalton membrane glycoprotein associated with multidrug resistance. 170- to 180-kilodalton membrane glycoprotein is an ATPase. J Biol Chem 263: 1454-1458, 1988.
19. Naito M, Hamada H, Tsuruo T. ATP/Mg2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 263: 11887-11891, 1988.
20. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41: 1967-1972, 1981.
21. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug- resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 42: 4730-4733, 1982.
22. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 43: 2267-2272, 1983.
23. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 43: 2905-2910, 1983.
24. Sato W, Fukazawa N, Nakanishi O, et al. Reversal of multidrug resistance by a novel quinoline derivative, MS- 209. Cancer Chemother Pharmacol 35: 271-277, 1995.
25. Natio M, Tsuruo T. Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement. Cancer Res 49: 1452-1455, 1989.
26. Naito M, Matsuba Y, Sato S, Hirata H, Tsuruo T. MS-209, a quinoline-type reversal agent, potentiates antitumor efficacy of docetaxel in multidrug-resistant solid tumor xenograft models. Clin Cancer Res 8: 582-588, 2002.
27. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P- glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987.
28. Tatsuta T, Naito M, Oh-hara T, Sugawara I, Tsuruo T. Functional involvement of P-glycoprotein in blood-brain barrier. J Biol Chem 267: 20383-20391, 1992.
29. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 256: 42-49, 2000.
30. Kataoka S, Naito M, Tomida A, Tsuruo T. Resistance to antitumor agent-induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 215: 199-205, 1994.
31. Sakamoto H, Mashima T, Kizaki A, et al. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent-induced apoptosis. Blood 95: 3214-3218, 2000.
32. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by S-p- bromobenzylglutathione cyclopentyl diester in glyoxalase I- overexpressing human lung cancer cells. Clin Cancer Res 7: 2513-2518, 2001.
33. Sakamoto H, Mashima T, Yamamoto K, Tsuruo T. Modulation of Hsp27 anti-apoptotic activity by methylglyoxalmodification. J Biol Chem 277: 45770-45775, 2002.
34. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose-regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 180: 97-104, 1999.
35. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II-directed drugs. Cancer Res 60: 2429-2434, 2000.
36. Ogiso Y, Tomida A, Kim HD, Tsuruo T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem. Biophys Res Commun 258: 448-452, 1999.
37. Ogiso Y, Tomida A, Tsuruo T. Nuclear localization of proteasomes participates in stress-inducible resistance of solid tumor cells to topoisomerase II-directed drugs. Cancer Res 62: 5008-5012, 2002.
38. Fujita N, Sato S, Katayama K, Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J Biol Chem 277: 28706-28713, 2002.
39. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 97: 10832-10837, 2000.
40. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3-phosphomositide- dependent kinase-1. J Biol Chem 277: 10346-10353, 2002.
41. Sato S, Fujita N, Tsuruo T. Interference with PDK1-Akt survival signaling pathway by UCN-01 (7-hydroxystaurosporine). Oncogene 21: 1727-1738, 2002.
42. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phosphatidylinositol 3′-kinase-Akt survival signaling pathway during topotecan-induced apoptosis. Cancer Res 60: 5303-5309, 2000.